AbbVie's Crohn's combo beats Skyrizi alone in Phase 2a TARGET-CD trial
Start here
AbbVie has reported Phase 2a TARGET-CD data at the 2026 UEGW congress showing that its Crohn's disease combination ABBV-466 — pairing Skyrizi with the anti-alpha-4-beta-7 integrin antibody trosunilimab — achieved higher endoscopic remission rates than either monotherapy group, meeting the primary endpoint. Presented as a late-breaker, the results suggest combination therapy could offer an advantage over single-agent treatment in Crohn's disease, and analysts have praised AbbVie's broader autoimmune strategy. The findings are mid-stage; larger confirmatory trials, regulatory decisions and questions of safety, dosing and commercial positioning remain open.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- BioSpacePickAs AbbVie’s Crohn’s combo beats Skyrizi in mid-stage test, analysts laud autoimmune vision
AbbVie presented Phase 2a TARGET-CD data as a late-breaker at the 2026 UEGW congress: ABBV-466, a Crohn's combination therapy pairing Skyrizi with the anti-alpha-4-beta-7 integrin antibody trosunilimab, achieved higher endoscopic remission rates than either monotherapy group, meeting the primary endpoint.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 20 00:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.